Harvard Bioscience, Inc. HBIO
7.96
(0.06)
(0.75%)
as of 25 Sep
- Market cap
- $36.5M
- P/E
- 0.0×
Follow HBIO
Insider Buys
alert about insiders buying in the last 12 month
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(135.62%) | (147.13%) | (78.65%) | (89.95%) | |
| (51.46%) | (54.86%) | (12.41%) | (13.32%) | ||
ROIC |
(76.24%) | (74.07%) | (0.14%) | (0.41%) | |
Return on Tangible Assets |
961.17% | (182.60%) | (34.35%) | (38.54%) | |
Average Days of Receivables |
50.59 | 67.66 | 62.19 | 60.27 | |
Free Cash Flow per Share |
1.53 | 1.10 | 0.29 | (0.40) | |
Free Cash Flow |
6.82 | 4.87 | 1.28 | (1.83) | |
Capital Expenditures |
(1.73) | (1.86) | (1.80) | (2.48) | |
Piotroski F-Score |
3.00 | 4.00 | 6.00 | 6.00 | |
| Other line items | |||||
Cash ROIC |
15.59% | 11.56% | 5.77% | 1.29% | |
Accounts Receivable Turnover |
7.01 | 5.60 | 6.10 | 6.64 | |
Accounts Payable Turnover |
7.19 | 8.68 | 7.05 | 6.71 | |
Inventory Turnover |
1.58 | 1.66 | 1.58 | 1.65 | |
Average Days of Payables |
50.22 | 36.38 | 54.27 | 61.83 | |
Days of Inventory on Hand |
209.60 | 207.26 | 227.91 | 220.84 | |
Tax Rate |
0.00 | (0.01) | (0.01) | (0.01) | |
Research and Development Expense of Revenue |
10.27% | 10.20% | 10.32% | 10.36% | |
Selling, General and Administrative Expense of Revenue |
43.43% | 42.70% | 43.07% | 43.34% | |
Share Based Compensation of Revenue |
2.70% | 2.14% | 1.77% | 1.62% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
(0.16) | (0.12) | (0.31) | (0.06) | |
Depreciation/Fixed assets |
11.04 | 11.54 | 1.49 | 1.37 | |
Capex/Depreciation |
(0.03) | (0.03) | (0.25) | (0.34) | |
Revenue per Share |
19.61 | 19.50 | 19.12 | 19.40 | |
Operating CF per Share |
1.92 | 1.52 | 0.69 | 0.14 | |
Capex per Share |
(0.39) | (0.42) | (0.40) | (0.55) | |
Capex to Sales |
0.02 | 0.02 | 0.02 | 0.03 | |
Net Profit Margin |
(61.62%) | (65.51%) | (11.44%) | (11.86%) |
Columns are period end dates